Jim Kastenmayer
General Counsel at ARRIVENT BIOPHARMA, INC.
Net worth: 143 362 $ as of 30/05/2024
Jim Kastenmayer active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ARRIVENT BIOPHARMA, INC. | General Counsel | 31/08/2023 | - |
| Corporate Secretary | 31/08/2023 | - |
Career history of Jim Kastenmayer
Former positions of Jim Kastenmayer
| Companies | Position | Start | End |
|---|---|---|---|
| SPYRE THERAPEUTICS, INC. | Chief Executive Officer | 23/08/2022 | 28/11/2022 |
| General Counsel | 14/07/2021 | 15/05/2023 | |
| President | 23/08/2022 | 28/11/2022 | |
| Corporate Secretary | 28/11/2022 | 15/05/2023 | |
| VIELA BIO, INC. | General Counsel | 31/12/2019 | 28/02/2021 |
| Corporate Secretary | 31/12/2019 | 28/02/2021 | |
| ASTRAZENECA PLC | General Counsel | 30/04/2012 | 30/11/2019 |
| Medimmune, Inc. | Corporate Officer/Principal | - | - |
Training of Jim Kastenmayer
| Georgetown University Law Center | Graduate Degree |
| Michigan State University | Doctorate Degree |
| University of Virginia | Undergraduate Degree |
Statistics
International
| United States | 8 |
| United Kingdom | 2 |
Operational
| General Counsel | 4 |
| Corporate Secretary | 3 |
| Graduate Degree | 1 |
Sectoral
| Health Technology | 6 |
| Consumer Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| SPYRE THERAPEUTICS, INC. | Health Technology |
| ARRIVENT BIOPHARMA, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Viela Bio, Inc.
 Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
| Medimmune, Inc. | Health Technology |
- Stock Market
- Insiders
- Jim Kastenmayer
- Experience
